Loading…
Zhejiang manufacturer of active pharmaceutical ingredients, mainly cardiovascular and anti-infective APIs, sold to generic drugmakers.
Zhejiang manufacturer of active pharmaceutical ingredients, mainly cardiovascular and anti-infective APIs, sold to generic drugmakers.
In one line: A small Chinese cardiovascular-API supplier.
Moat: none (scale). Commodity API producer competing mainly on cost and regulatory filings.
Headquarters: Taizhou, Zhejiang, China · Employees: 1,328
Size Zhejiang Ausun Pharmaceutical (603229.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $893M, the 2535th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥7.17 on 6 Nov 2026.
Performance Over six months the shares fell 27.1%, against -11.9% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 1.0% over the last twelve months (peer median +1.7%); the operating margin is 0.2% (peer median 6.7%).
Valuation It trades at 7.1× enterprise value to sales against a peer median of 4.3× (3rd most expensive of 18).
Capital Return on invested capital runs 2.3 points below its cost of capital (5.0% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥757M | CN¥787M | CN¥790M | CN¥814M | CN¥763M |
| Revenue growth | — | 0% | -3% | +7% | — |
| Gross profit | CN¥406M | CN¥399M | CN¥414M | CN¥435M | CN¥380M |
| EBITDA | n/a | CN¥187M | CN¥243M | CN¥282M | CN¥238M |
| Net income | -CN¥4.53M | CN¥131M | CN¥207M | CN¥254M | CN¥235M |
| Free cash flow | -CN¥50.4M | CN¥52.1M | CN¥66.6M | CN¥58.4M | -CN¥151M |
| Capital expenditure | CN¥96.4M | CN¥104M | CN¥111M | CN¥163M | CN¥272M |
| Total debt | CN¥407M | CN¥540M | CN¥416M | CN¥413M | CN¥391M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Ausun Pharmaceutical 603229.SS | $893M | -27% | +1% | 0% | 7.1× | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | $1.39B | -9% | +9% | -13% | 4.9× | n/a |
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.86B | +8% | +10% | 12% | 3.4× | 7.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603229.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.0% | -6.5% | 5th lowest of 20 |
| 6-month return | -27.1% | -11.9% | 6th lowest of 20 |
| Distance from 52-week high | -33.7% | -35.5% | 10th highest of 21 |
| Revenue growth (TTM) | +1.0% | +1.7% | 9th lowest of 19 |
| Operating margin | 0.2% | 6.7% | 7th lowest of 19 |
| EV / Sales | 7.1× | 4.3× | 3rd most expensive of 18 |
| ROIC minus cost of capital | -2.3 pp | -2.2 pp | 9th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $893M | -27% | +1% | 0% | 7.1× | n/a | n/a |
| Aarti Pharmalabs AARTIPHARM.NS | India | $892M | +19% | +13% | 18% | 4.3× | n/a | n/a |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $894M | -8% | -1% | -2% | 6.1× | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $887M | -32% | n/a | n/a | n/a | n/a | n/a |
| Aktis Oncology AKTS | United States | $880M | -15% | +337% | -1,150% | 57.5× | n/a | n/a |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $907M | -12% | -25% | 2% | 2.9× | 16.2% | -0.2% |
| Wanbangde Pharmaceutical 002082.SZ | China | $909M | -65% | -11% | -3% | 5.9× | -1.2% | -39.5% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $909M | -33% | -14% | -29% | 5.2× | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $874M | -30% | +9% | 12% | 0.7× | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $874M | -2% | +2% | 9% | 2.1× | 2.5% | +12.4% |
| Bide Pharmatech 688073.SS | China | $912M | +5% | +10% | 19% | 3.6× | 16.7% | +27.7% |
| Oric Pharmaceuticals ORIC | United States | $914M | 0% | n/a | n/a | n/a | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $861M | -7% | +2% | 14% | 1.9× | 4.8% | +22.5% |
| Dezhan Healthcare 000813.SZ | China | $928M | -18% | -10% | -121% | 15.8× | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $930M | -24% | -6% | 5% | 4.4× | 33.2% | +4.2% |
| Nxera Pharma 4565.T | Japan | $932M | +63% | +24% | 14% | 5.1× | 16.2% | +27.3% |
| Kaken Pharmaceutical 4521.T | Japan | $854M | -8% | -7% | 11% | 0.9× | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $942M | -20% | +5% | 9% | 4.7× | n/a | n/a |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $948M | -10% | -6% | 3% | 1.0× | -6.8% | -0.7% |
| Luye Pharma 2186.HK | Hong Kong | $839M | -36% | +3% | 18% | 1.2× | -10.5% | +1.9% |